Clinical Trials Logo

Filter by:
NCT ID: NCT03574545 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Study Comparing Two VAY736 Drug Products in Patients With Rheumatoid Arthritis

Start date: December 19, 2018
Phase: Phase 1
Study type: Interventional

This study will assess the safety and pharmacokinetic comparability of two VAY736 drug products in patients with rheumatoid arthritis.

NCT ID: NCT03515993 Active, not recruiting - Gynecologic Cancer Clinical Trials

Follow-up in Gynecological Cancer Survivors

Start date: February 21, 2019
Phase:
Study type: Observational

A cross-sectional prospective study of follow-up in gynecologic cancer patients after primary treatment

NCT ID: NCT03507556 Active, not recruiting - Revascularization Clinical Trials

Regeneration of Immature Teeth. Case Series

Start date: June 28, 2010
Phase: N/A
Study type: Interventional

This clinical study aims to investigate the predictability of revascularization procedure of immature necrotic human permanent teeth with apical periodontitis. The quality of root development (thickness and length) will be assessed radiographically.

NCT ID: NCT03503630 Active, not recruiting - Clinical trials for Locally Advanced Rectal Cancer

Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma

Start date: July 20, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to show that the addition of COMPOUND 2055269, an immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response rate in patients with locally advanced rectal cancer.

NCT ID: NCT03466411 Active, not recruiting - Crohn's Disease Clinical Trials

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

GALAXI
Start date: April 13, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

NCT ID: NCT03403985 Active, not recruiting - Dental Pulp Capping Clinical Trials

Long-term Evaluation of Direct Pulp Capping

Start date: June 1, 2017
Phase: N/A
Study type: Interventional

Calcium hydroxide and mineral trioxide aggregate have been used in vital pulp therapy with variable outcomes recorded by different study. They will be compared when used for direct pulp capping in cariously exposed mature permanent teeth.

NCT ID: NCT03299413 Active, not recruiting - Clinical trials for Inflammatory Bowel Diseases

Use of Mesenchymal Stem Cells in Inflammatory Bowel Disease

Start date: June 5, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

Scientists hypothesize that directly or parentally injecting Mesenchymal stem cells (MSCs) to affected areas will have a positive impact through reducing or abolishing intestinal inflammation in part via inhibition of neutrophil Myeloperoxidase (MPOx) activity. Inhibiting MPOx should modify disease progression as well as reduce colitis associated cancer risk.

NCT ID: NCT03186690 Active, not recruiting - Clinical trials for Irreversible Pulpitis

Similar Outcomes of Vital Pulp Therapy Using Mineral Trioxide Aggregate or Biodentine™

Start date: July 4, 2013
Phase: N/A
Study type: Interventional

This study aimed to evaluate the clinical performance of White MTA (MTA, Angelus, Londrina, Brazil) and Biodentine™ in pulp capping of cariously exposed mature permanent teeth. The investigator performed a prospective longitudinal randomized controlled study utilizing vital permanent mature teeth with deep caries. Patients will be divided randomly into Biodentine™ and MTA groups; Teeth will be assessed clinically and radiographically prior to the procedure. Caries will be excavated under local anesthesia, hemostasis is achieved after pulp exposure using NaOCl and will be capped with Biodentine™ or MTA. Clinical and radiographical follow-up will be performed by a blinded calibrated evaluator after six months and one year, and yearly after.

NCT ID: NCT03088540 Active, not recruiting - Clinical trials for Non-small-cell Lung Carcinoma

Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Start date: May 29, 2017
Phase: Phase 3
Study type: Interventional

The primary objectives of the study are: - To compare the overall survival (OS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 in ≥50% of tumor cells - To compare the progression-free survival (PFS) of cemiplimab versus standard-of-care platinum-based chemotherapies in the first-line treatment of patients with advanced or metastatic NSCLC whose tumors express PD-L1 in ≥50% of tumor cells The key secondary objective of the study is to compare the objective response rate (ORR) of cemiplimab versus platinum-based chemotherapies

NCT ID: NCT03069209 Active, not recruiting - Clinical trials for Premature Ovarian Failure

Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)

Start date: January 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open label, single arm, single center investigation to assess the safety and efficacy of purified adult autologous bone marrow derived specific populations of stem cells and mesenchymal stem cells injected into the ovaries (intraovarian injection), through a 12 week follow-up period. The investigators' chosen model of study is based on increasing the efficiency of the approach by choosing an autologous model which preserves the genetic composition of an individual that is vital in infertility conditions. Additionally the approach involves transplanting a combination of specific purified stem cell types which all aid in ovarian function recovery.